Vertex Pharmaceuticals (VRTX) Stock Library

Competitive view

VRTX vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Vertex Pharmaceuticals

VRTX

YouTube

Latest video

Q1 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

VRTX

—

Vertex Pharmaceuticals

ISRG

$155.16B

Intuitive Surgical

JNJ

$564.11B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

VRTX

—

Vertex Pharmaceuticals

ISRG

53.2x

Intuitive Surgical

JNJ

27.2x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

VRTX

—

Vertex Pharmaceuticals

ISRG

37.2x

Intuitive Surgical

JNJ

18.4x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

VRTX

—

Vertex Pharmaceuticals

ISRG

23.0%

Intuitive Surgical

JNJ

9.9%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

VRTX

—

Vertex Pharmaceuticals

ISRG

18.8%

Intuitive Surgical

JNJ

-52.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

VRTX

—

Vertex Pharmaceuticals

ISRG

30.9%

Intuitive Surgical

JNJ

27.4%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

VRTX

—

Vertex Pharmaceuticals

ISRG

66.3%

Intuitive Surgical

JNJ

68.0%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

VRTX

—

Vertex Pharmaceuticals

ISRG

28.1%

Intuitive Surgical

JNJ

21.8%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

VRTX

—

Vertex Pharmaceuticals

ISRG

17.2%

Intuitive Surgical

JNJ

26.4%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

VRTX

—

Vertex Pharmaceuticals

ISRG

1.4%

Intuitive Surgical

JNJ

2.2%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

VRTX

—

Vertex Pharmaceuticals

ISRG

0.50x

Intuitive Surgical

JNJ

67.73x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

VRTX

—

Vertex Pharmaceuticals

ISRG

4.61x

Intuitive Surgical

JNJ

1.02x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

VRTX

—

Vertex Pharmaceuticals

ISRG

1.51

Intuitive Surgical

JNJ

0.26

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

VRTX

—

Vertex Pharmaceuticals

ISRG

—

Intuitive Surgical

JNJ

2.2%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

VRTX

—

Vertex Pharmaceuticals

ISRG

30.7%

Intuitive Surgical

JNJ

7.9%

Johnson & Johnson

Vertex Pharmaceuticals

Market context for VRTX

VRTX vs. two close competitors

Episode archive for VRTX